Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sphingomyelin phosphodiesterase acid-like 3B (SMPDL3B)
- Target
- SMPDL3B
- Molecular classification
- Enzyme, Phosphodiesterase
01
Overview
Sphingomyelin phosphodiesterase acid-like 3B (SMPDL3B) is an enzyme highly expressed on the surface of macrophages and dendritic cells, influencing macrophage lipid composition and membrane fluidity. It acts as a negative regulator of innate immune signaling, controls Toll-like receptor signaling in podocytes, and is involved in various disease mechanisms including immune-related kidney disorders and certain cancers. Its structure features a unique substrate binding site, allowing activity on substrates like sphingomyelin and, potentially, CDP-choline, ATP, and ADP. Rituximab may modulate SMPDL3B activity, impacting kidney diseases where this molecule has biomarker and therapeutic implications.
- Other names
- Acid sphingomyelinase-like phosphodiesterase 3BSMPDL-3bSMPDL3BSMPDL3b
02
Mechanism of action
Modulation of immune responses by enzymatic regulation of lipid mediators; Interference with Toll-like receptor signaling
03
Biological functions
Regulation of innate immune signalingModulation of lipid compositionControl of membrane fluidityToll-like receptor signaling
04
Disease associations
Kidney disorders (e.g., risk and function in nephrotic syndrome and podocytes)Cancer (e.g., biomarker in prostate cancer)Immune-related disorders
05
Safety considerations
Off-target effect of rituximab on kidney function via SMPDL3B modulation
06
Interacting drugs
Rituximab (off-target interaction in kidney disorders)
07
Biomarkers
SMPDL3B gene expression as a predictive marker in localized prostate cancer
Beyond the preview
Go deeper on Sphingomyelin phosphodiesterase acid-like 3B (SMPDL3B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sphingomyelin phosphodiesterase acid-like 3B (SMPDL3B).